Familial amyotrophic lateral sclerosis (FALS) has been linked to mutations in the homodimeric enzyme Cu/Zn superoxide dismutase 1 (SOD1). Assay by transient expression in primate cells of six FALS mutant enzymes revealed a continuum of enzymatic activity bounded by the enzyme carrying the mutation Gly-85 -Arg, which was inactive, and mutant enzyme G37R carrying the Gly-37 -> Arg change, which retained full specific activity but displayed a 2-fold reduction in polypeptide stability. (3, 4, 10, 11) . Initial studies of SOD1 activity in blood from six FALS cases reported 50-65% reductions in enzyme activity as a function of total protein (3, 12, 13) , and it was suggested that FALS-linked mutations affect either enzyme activity or polypeptide stability, causing a nearly complete loss of function from the mutant allele. However, subsequent studies have reported that individuals heterozygous for a His-46 --Arg mutation, which lies in the active-site domain, possess blood enzyme activity levels that are 80%o of normal (6). One problem in interpreting these data is that others have demonstrated 2-to 3-fold variability in the SOD1 levels of circulating erythrocytes in normal individuals (11, 12, 14) , casting doubt on the significance of blood SOD1 levels. In the present study, we examined mutant SOD1 subunits in nonerythroid cells, using lymphoblasts derived from FALS individuals and DNA transfection into primate cells, to determine the intrinsic specific activity and stability of wild-type and mutant Hu-SOD1 polypeptides.
Familial amyotrophic lateral sclerosis (FALS) is an agedependent autosomal dominant disorder (1) (2) (3) (4) in which mutations in the homodimeric enzyme Cu/Zn superoxide dismutase 1 (SOD1) have been linked to disease in 20-50%o of FALS families (3) (4) (5) (6) (7) . The human SOD1 (HuSOD1) polypeptide is encoded by a single gene on chromosome 21 (8) , producing an 153-amino acid metalloenzyme that catalyzes the conversion of 0-into 02 and H202 (5, 8, 9) . To date, 16 different SOD1 mutations have been reported in heterozygous individuals with FALS (3, 4, 10, 11) . Initial studies of SOD1 activity in blood from six FALS cases reported 50-65% reductions in enzyme activity as a function of total protein (3, 12, 13) , and it was suggested that FALS-linked mutations affect either enzyme activity or polypeptide stability, causing a nearly complete loss of function from the mutant allele. However, subsequent studies have reported that individuals heterozygous for a His-46 --Arg mutation, which lies in the active-site domain, possess blood enzyme activity levels that are 80%o of normal (6) . One problem in interpreting these data is that others have demonstrated 2-to 3-fold variability in the SOD1 levels of circulating erythrocytes in normal individuals (11, 12, 14) , casting doubt on the significance of blood SOD1 levels. In the present study, we examined mutant SOD1 subunits in nonerythroid cells, using lymphoblasts derived from FALS individuals and DNA transfection into primate cells, to determine the intrinsic specific activity and stability of wild-type and mutant Hu-SOD1 polypeptides.
MATERIALS AND METHODS
Cloning and Mutagenesis of Human SOD) Genes. A cDNA copy of the human SOD) gene was obtained by reverse transcription-coupled polymerase chain reaction (PCR) amplification using primers (sense primer, GTCGACAAG-CATGGCCACGAAGGCCGTGTGC; antisense primer, CCGGTCGACAGGGAATGTIIATTGGGCGATCC) that contained terminal Sal I sites and converted sequences surrounding the start codon (underlined) from human GAGT-TATGG to mouse CAAGCAIQG, enhancing the consensus sequence for translation initiation (13) . The PCR product was blunt-ligated into the Sma I site of Bluescript II KS(-) and was verified by sequencing. Mutations were engineered by oligonucleotide-directed mutagenesis by using a kit purchased from Amersham. The entire open reading frame of each mutant was confirmed by sequencing.
Analysis of SOD1 Enzyme Activity. Wild-type and mutant SOD) genes were cloned into the vector pEF-BOS (15) and transfected transiently into COS-1 cells (16) . After 48 h, cells were lysed by a freeze/thaw cycle in water, which was then adjusted to contain 0.125 M Tris chloride (pH 6.8), 20%o (vol/vol) glycerol, 0.025% bromophenol blue, and 0.1% Nonidet P-40. After centrifugation at 10,000 x g for 5 min, the supernatant was separated by electrophoresis on 7.5% polyacrylamide gels, and SOD1 activities were determined as described (17) . The intensities of the SOD1 activity signals seen in our assay gels fall within a linear range bounded by 0.0625 ug and 2 pg of purified human erythrocyte SOD1.
Calculation of SOD1 Enzyme Specific Activity. Extracts of COS-1 cells were fractionated on SDS/polyacrylamide gels and immunoblotted with either of two polyclonal antisera raised against a synthetic HuSODi peptide (amino acids 125-137; Asp-Asp-Leu-Gly-Lys-Gly-Gly-Asn-Glu-Glu-SerThr-Lys) or intact erythrocyte HuSODi polypeptide. Both antisera specifically recognized HuSODi, with weak crossreactivity for COS-1 SOD1. The immunoreactivity of these antisera was fully blocked by competition with excess peptide or whole protein (not shown).
SOD1 assay gels and immunoblots were quantified by using a Stratagene Eagle Eye II to digitize images. Pixel densities of SODi-associated bands were quantified by using the program 
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into equivalent dishes of COS-1 cells as described (16 (18) with a pH gradient of 4-6.5, followed by fluorography and autoradiography. RESULTS Specific Activity of Mutant SOD1 Enzymes. To examine directly whether FALS-associated mutations affect the catalytic activity of HuSODi enzyme, we expressed transiently mutant polypeptides in monkey (COS-1) cells (Fig. 1 ). Human and monkey SOD1 homodimeric enzymes were distinguishable after electrophoretic separation in nondenaturing polyacrylamide gels and in situ evaluation of activity (17, 20, 21) (Fig. 1A) . The transfection of COS-1 cells with wild-type HuSOD1 expression plasmids produced a new species of free-radical scavenging activity (Fig. 1A , lane 2), which comigrated with purified erythrocyte HuSODl (Fig. lA, lane 9). In most experiments, expression of HuSODi was restricted to a relatively few cells, and the human subunits were found predominantly in homodimers. Cells transfected with all but one of the mutant SOD1 vectors produced novel activities, attributable to vector-encoded SOD1 enzyme (Fig.   1A, lanes 3-8) . Further, enzymes carrying mutations that alter charge, Gly-37 -Arg and Gly-41 -* Asp, exhibited electrophoretic migration different from that of wild-type HuSODl in these assay gels (Fig. 1A , lanes 4 and 5; mutant enzymes G37R and G41D). One mutation, Gly-85 -) Arg, also caused the mutant polypeptide (G85R) to migrate anomalously on SDS/PAGE (Fig. 1B, lane 6 letter code-only G85R lacked demonstrable evidence of activity (see lanes 6 of Fig. 1 A and B) . Presumably, the G85R mutant is improperly folded and is inactive or fails to enter the activity assay gel. The ratio of enzymatic activity to accumulated protein level [determined by quantitative immunoblotting with newly made HuSOD1 antibodies (Fig. 1B) ] was used to calculate specific activity (Fig. 1C) . Although the G85R mutant was inactive, the A4V (Ala-4 --Val mutation), G41D, G93C (Gly-93 -3 Cys mutation), and 1113T (Ile-113 --Thr mutation) mutants retained 30-65% of wild-type specific activity. Notably, the specific activity of the G37R mutant was equal to or greater than that of the wild-type SOD1. Moreover, homodimeric, active, enzymes were identified for four of the six mutants after electrophoretic separation and assay in 8 M urea (20, 22)/polyacrylamide gels (not shown); the specific activity of the G37R mutant remained high. Thus, we con- (Fig. 3) . Three active species were detected on activity gels of G37R lymphoblast extracts [the fastest and slowest migrating bands, respectively, comigrated with wildtype and G37R homodimeric enzyme produced in COS-1 cells (Fig. 3A, lanes 3 and 4) ], while normal human lymphoblasts contained a single species (lane 5). In the mutant line, one species migrated between the wild-type and mutant homodimers; we interpret this to represent active mutant/ wild-type heterodimers (20, 22) . The level of mutant homodimer activity was =50M of either the heterodimer or the wild-type homodimer, which were of comparable activities.
Overall, the level of total SODi activity was 60-80%o of normal lymphoblasts, with the total (wild type plus mutant) amount of SOWi polypeptide diminished by -40% (Fig. 3 B and C).
To determine whether the reduced abundance of G37R polypeptide results from diminished polypeptide stability in these cells, we examined the relative synthetic rate and stability of SODi polypeptides (Fig. 3D) . Following pulse (15 min) labeling with [35S~cysteine, two-dimensional SDS/ PAGE analysis of immunoprecipitated SODi from wild-type lymphoblast extracts revealed two major SODi isoforms (Fig. 3D, filled arrowheads) , as well as additional isoforms of lower abundance. The molecular basis for these isoforms is not known, but each must be rapidly generated from the initial translation product. Analysis of SODi immunoprecipitated from G37R lymphoblasts revealed a prominent more basic isoform (Fig. 3D, open arrowhead) , as would be expected for the replacement of glycine with arginine. This more basic isoform (open arrowhead) was unambiguously identified as the mutant species on the basis of comigration with G37R polypeptides produced in COS cells (Fig. 3C) . After 24 h of chase, the mutant polypeptide was selectively diminished with a half-life less than that of the wild-type polypeptide. However, there was no obvious reduction in the half-life of the wild-type subunit in G37R lymphoblasts.
DISCUSSION
Assay of the effect of six of the known FALS-linked mutations on HuSODi activity has revealed a continuum bounded by G85R, which has no activity, and G37R, which possesses 40-60% of wild-type subunit activity (diminished abundance with full specific activity). Although FALS is a dominant genetic disease (1) (2) (3) (4) , heterozygosity for any of the six mutants described here should only result in a net loss of 20-50%6 of the total expected activity (Fig. 4) (19) . The radiolabeled SODi polypeptide band was quantified on a Molecular Dynamics Phosphorlmager. Half-lives of the wild-type HuSOD1 and each mutant were estimated as described in text. The graph displays data from three experiments in which cells were collected at 0 and 24 h of chase and two experiments in which cells were collected at 0, 12, 24, and 48 h. The order of plot lines is noted to the right of the graph; A4V and G85R overlap. acted in a dominant manner to diminish the activity or stability of wild-type protein through heterodimerization (3, 23) . Ofthe mutants we have analyzed here, the level of SODi activity in blood from an individual with the G85R mutation has been reported to be reduced -65%, whereas the level of activity in A4V cases was reduced -50o (3). Although these data from FALS blood are consistent with a partially dominant negative effect (3), it is unclear whether the values obtained from blood are sufficiently accurate to allow judgments regarding dominant effects, as blood SODi levels apparently vary considerably among individuals (11) (12) (13) . Our results from the human G37R lymphoblasts demonstrate that heterodimerization with mutant subunits does not appreciably alter the activity or stability of wild-type subunits. When viewed together with previous studies, which have demonstrated that wild-type HuSOD1 activity is unaffected by heterodimeric interaction with chemically inactivated subunits (24), we believe that it is unlikely that the activity and the stability of the wild-type SODi subunits are affected by the properties of their dimeric partner. Thus, in FALS, any diminution in SOD1 activity will likely be restricted to the mutant subunit only, with the wild-type subunit continuing to provide 50% of the normal level of activity.
The linkage of FALS to mutations in SOD1 implicates free-radical damage as a mechanism of motor neuron degeneration (3, 4, 10, 11, 25, 26) , and we have recently obtained immunocytochemical evidence of abundant SOD1 expression in motor neurons (C. A. Pardo, Z.-S.X., D.L.P., S.S.S., and D.W.C., unpublished data). However, we demonstrate in our present study that the potential activity of some mutants remains surprisingly robust. Unless there are celltype-specific modifiers of SOD1 activity (for which there is no evidence), the enzyme activity values we measured in our cell cultures are likely to be applicable to all cells, including motor neurons. Moreover, in most heterozygous individuals, we predict that the activity and stability of the wild-type subunit are unaffected by heterodimerization. Therefore, if motor neuron degeneration in SOD1-linked FALS results from free-radical damage, then a modest reduction in total SODi activity, involving only the mutant subunit, must be sufficient to elevate free-radical levels to toxic concentrations in some cases. However, whether free-radical damage alone underlies motor neuron diseases is made tenuous by the realization that free radicals are cleared by a number of other cellular components, including enzymes involved in glutathione reduction and oxidation; Mn-SOD, a mitochondrial matrix enzyme; and EC-SOD, a glycosylated Cu/Zn enzyme found in the extracellular space (9, 27) . Furthermore, a recent study of FALS individuals with the A4V mutation found no evidence of increased free-radical damage (10) . The absence of oxidative damage, combined with our finding that some SODi mutants are relatively stable and active, strongly supports the view that, in some SOD1-linked FALS cases, motor neuron degeneration may not result from a loss of SODi activity. Although it is possible that the degree of activity retained by mutant enzymes will correlate with disease severity or patient survival, a plausible alternative view is that at least some SODi mutants either affect processes unrelated to free-radical metabolism or acquire properties that injure neurons by mechanisms unrelated to°2 metabolism.
Note Added in Proof: Additional evidence that mutant SOD1 gains injurious properties arises from the recent report of motor neuron disease in a transgenic mouse line expressing a FALS-linked SOD1 mutation (Gly-93 -+ Arg) (28) . Since bulk SOD1 activity levels were reported to be elevated in these transgenic animals, the mutant SOD1 must retain significant activity. Moreover, we have recently observed motor neuron disease in transgenic mice expressing G37R HuSOD1, which we have shown here to retain full specific activity and to be relatively stable.
